Status:
TERMINATED
Sildenafil to Treat HIV-Associated Pulmonary Hypertension
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
HIV
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will examine how blood pressure in the lungs is controlled in healthy people, people with HIV and people with HIV and pulmonary artery hypertension (high blood pressure in the lungs, also c...
Detailed Description
HIV infection has been associated with an increased prevalence of pulmonary hypertension. In addition, recent data suggests that a state of endothelial dysfunction develops in HIV disease secondary to...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- All volunteer subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study. Eligibility in the study is determined prior to enrollment on the basis of the following inclusion and exclusion criteria.
- For Healthy Volunteers:
- Males or females, 18 years of age or older.
- No history of HIV infection.
- EKG and echocardiogram with no evidence of clinical relevant heart disease (including TRV less than 2.5 m/s)
- No history of causes of pulmonary hypertension such as collagen vascular disease, chronic liver disease with ALT or AST greater than 2 times the upper limit of normal or cirrhosis of the liver, chronic thromboembolic disease, congenital heart defects, or pulmonary parenchymal disease with hypoxemia.
- No history of diseases thought to be related to development of endothelial dysfunction including systemic hypertension or diabetes requiring drug therapy, hypercholesterolemia and obesity.
- No history of anemia, thrombocytopenia or coagulopathy.
- No history of renal insufficiency.
- No medical conditions requiring chronic medication use with the exception of:
- Heartburn, GERD
- Environmental allegeries, post nasal drip or non-allergic rhinitis
- Asthma with no history of oral steroid use, weekly inhaled steroids, or hospitalization for asthma exacerbation.
- Dermatologic conditions that do not require the use of oral steroids or other immunosuppressants.
- No more than 20 cigarettes per year for the previous 2 years and no cigarette use for 30 days prior to the screening evaluation until completion of the study.
- For HIV Positive Volunteers:
- Males or females, 18 years of age or older.
- Diagnosis of HIV infection.
- Under the care of a primary care physician.
- No history of other potential causes of pulmonary hypertension such as collagen vascular disease, chronic liver disease with ALT or AST greater than 2 times the upper limit of normal or cirrhosis of the liver, chronic thromboembolic disease, congenital heart defects, or pulmonary parenchymal disease with hypoxemia.
- For stage 3 enrollment: symptomatic pulmonary hypertension with MPAP greater than or equal to 25 mmHg and six-minute walk distance between 150-450 m.
- EXCLUSION CRITERIA:
- For Healthy volunteers:
- Current pregnancy, lactation or women not currently using medically acceptable birth control. (All women of childbearing age will be required to have a screening urine or blood pregnancy test)
- Contraindication to MRI scanning including individuals with the following devices:
- A) Central nervous system aneurysm clips
- B) Implanted neural stimulator
- C) Implanted cardiac pacemaker or defibrillator prior to enrollment
- D) Cochlear implant
- E) Ocular foreign body (e.g. metal shavings)
- F) Insulin pump
- G) Metal shrapnel or bullet
- Contraindications to MRI contrast agent administration:
- Inability to provide informed written consent for participation in the study.
- Chronic, medically refractory atrial tachyarrhythmias
- Symptoms of heart failure
- Mean PA greater than 25 mmHg or PVR greater than 1.5 wood units, or PCWP greater than 15 mmHg
- History of recreational drug use with the exception of marijuana. No Marijuana use within 3 months of protocol screening through completion of the study.
- Volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer.
- For HIV Positive Volunteers:
- Current pregnancy, lactation or women not currently using medically acceptable birth control.
- Active, untreated opportunistic infection with the exception of oral thrush or neoplasm with the exception of Kaposi's Sarcoma.
- Any of the following medical conditions:
- A) Severe renal insufficiency (on hemodialysis or serum creatinine greater than 2.5 mg/dl) or (CrCl less than 20 ml/min).
- B) Severe coagulopathy (platelets less than 100,000, PT INR greater than 1.5, PTT greater than 40 s)
- Chronic, medically refractory atrial tachyarrhythmias
- Current recreational drug use or use within 4 weeks of protocol screening with the exception of marijuana
- Contraindication to MRI scanning including individuals with the following devices:
- A) Central nervous system aneurysm clips
- B) Implanted neural stimulator
- C) Implanted cardiac pacemaker or defibrillator prior to enrollment
- D) Cochlear implant
- E) Ocular foreign body (e.g. metal shavings)
- F) Insulin pump
- G) Metal shrapnel or bullet
- Contraindications to MRI contrast agent administration:
- A) Individuals with hemoglobinopathies
- Volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer.
Exclusion
Key Trial Info
Start Date :
May 12 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00327080
Start Date
May 12 2006
End Date
March 18 2009
Last Update
December 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892